Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.

IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Journal of Nuclear Medicine Pub Date : 2023-11-01 Epub Date: 2023-09-07 DOI:10.2967/jnumed.123.266046
Stefan A Koerber, Manuel Röhrich, Leon Walkenbach, Jakob Liermann, Peter L Choyke, Christoph Fink, Cathrin Schroeter, Anna-Maria Spektor, Klaus Herfarth, Thomas Walle, Jeremie Calais, Hans-Ulrich Kauczor, Dirk Jaeger, Juergen Debus, Uwe Haberkorn, Frederik L Giesel
{"title":"Impact of <sup>68</sup>Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.","authors":"Stefan A Koerber, Manuel Röhrich, Leon Walkenbach, Jakob Liermann, Peter L Choyke, Christoph Fink, Cathrin Schroeter, Anna-Maria Spektor, Klaus Herfarth, Thomas Walle, Jeremie Calais, Hans-Ulrich Kauczor, Dirk Jaeger, Juergen Debus, Uwe Haberkorn, Frederik L Giesel","doi":"10.2967/jnumed.123.266046","DOIUrl":null,"url":null,"abstract":"<p><p>Since the development of fibroblast activation protein-targeted radiopharmaceuticals, <sup>68</sup>Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for detecting primary and metastatic lesions in many types of tumors. However, there is currently a lack of reliable data regarding the clinical impact of this family of probes. To address this gap, the present study aimed to analyze the clinical impact of <sup>68</sup>Ga-FAPI PET/CT by examining a large cohort of patients with various tumors. <b>Methods:</b> In total, 226 patients (137 male and 89 female) were included in this retrospective analysis. Pancreatic cancer and head and neck cancers were the most common tumor types in this cohort. TNM stage and oncologic management were initially determined with gold standard imaging, and these results were compared with <sup>68</sup>Ga-FAPI PET/CT. Changes were classified as major and minor. <b>Results:</b> For 42% of all patients, TNM stage was changed by <sup>68</sup>Ga-FAPI PET/CT results. Most of these changes resulted in upstaging. A change in clinical management occurred in 117 of 226 patients. Although a major change in management occurred in only 12% of patients, there was a significant improvement in the ability to accurately plan radiation therapy. In general, the highest clinical impact of <sup>68</sup>Ga-FAPI PET/CT imaging was found in patients with lung cancer, pancreatic cancer, and head and neck tumors. <b>Conclusion:</b> <sup>68</sup>Ga-FAPI PET/CT is a promising imaging probe that has a significant impact on TNM stage and clinical management. <sup>68</sup>Ga-FAPI PET/CT promises to be a crucial new technology that will improve on conventional radiologic imaging methods such as contrast-enhanced CT and contrast-enhanced MRI typically acquired for cancer staging.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626373/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2967/jnumed.123.266046","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Since the development of fibroblast activation protein-targeted radiopharmaceuticals, 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for detecting primary and metastatic lesions in many types of tumors. However, there is currently a lack of reliable data regarding the clinical impact of this family of probes. To address this gap, the present study aimed to analyze the clinical impact of 68Ga-FAPI PET/CT by examining a large cohort of patients with various tumors. Methods: In total, 226 patients (137 male and 89 female) were included in this retrospective analysis. Pancreatic cancer and head and neck cancers were the most common tumor types in this cohort. TNM stage and oncologic management were initially determined with gold standard imaging, and these results were compared with 68Ga-FAPI PET/CT. Changes were classified as major and minor. Results: For 42% of all patients, TNM stage was changed by 68Ga-FAPI PET/CT results. Most of these changes resulted in upstaging. A change in clinical management occurred in 117 of 226 patients. Although a major change in management occurred in only 12% of patients, there was a significant improvement in the ability to accurately plan radiation therapy. In general, the highest clinical impact of 68Ga-FAPI PET/CT imaging was found in patients with lung cancer, pancreatic cancer, and head and neck tumors. Conclusion: 68Ga-FAPI PET/CT is a promising imaging probe that has a significant impact on TNM stage and clinical management. 68Ga-FAPI PET/CT promises to be a crucial new technology that will improve on conventional radiologic imaging methods such as contrast-enhanced CT and contrast-enhanced MRI typically acquired for cancer staging.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
68Ga FAPI PET/CT对226名不同癌症患者的分期和肿瘤管理的影响。
自从开发成纤维细胞活化蛋白靶向放射性药物以来,68Ga成纤维细胞激活蛋白抑制剂(FAPI)PET/CT已被发现适用于检测许多类型肿瘤的原发性和转移性病变。然而,目前缺乏关于该探针家族的临床影响的可靠数据。为了解决这一差距,本研究旨在通过检查患有各种肿瘤的大队列患者来分析68Ga FAPI PET/CT的临床影响。方法:共有226名患者(137名男性和89名女性)被纳入本回顾性分析。胰腺癌癌症和头颈癌是该队列中最常见的肿瘤类型。TNM分期和肿瘤处理最初用金标准成像确定,并将这些结果与68Ga FAPI PET/CT进行比较。变化分为主要变化和次要变化。结果:68Ga-FAPI-PET/CT结果显示,42%的患者TNM分期发生改变。这些变化中的大多数都导致了崛起。226名患者中有117名发生了临床管理方面的变化。尽管只有12%的患者在管理上发生了重大变化,但准确计划放射治疗的能力有了显著提高。总体而言,68Ga-FAPI PET/CT成像的临床影响最高的是癌症、癌症胰腺癌和头颈部肿瘤患者。结论:68Ga FAPI PET/CT是一种很有前途的显像探针,对TNM分期和临床管理有重要影响。68Ga-FAPI PET/CT有望成为一项关键的新技术,它将改进传统的放射学成像方法,如通常用于癌症分期的对比增强CT和对比增强MRI。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Nuclear Medicine
Journal of Nuclear Medicine 医学-核医学
CiteScore
13.00
自引率
8.60%
发文量
340
审稿时长
1 months
期刊介绍: The Journal of Nuclear Medicine (JNM), self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), provides readers worldwide with clinical and basic science investigations, continuing education articles, reviews, employment opportunities, and updates on practice and research. In the 2022 Journal Citation Reports (released in June 2023), JNM ranked sixth in impact among 203 medical journals worldwide in the radiology, nuclear medicine, and medical imaging category.
期刊最新文献
C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy of Multiple Myeloma Using [99mTc]Tc-PentixaTec. Debating the Future of Nuclear Medicine: The Greek Experience. Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis Identification of (R)-[18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development Value of68Ga-FAPI-04 and18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1